HOLX (Hologic Inc)
Insider Trading Activity
Every open-market purchase and sale reported by HOLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | Nanaz Mohtashami | Director | A | — | — |
| 2026-03-02 | LUDWIG HANTSON | Director | A | — | — |
| 2026-03-02 | Amy McBride Wendell | Director | A | — | — |
| 2026-03-02 | Martin D Madaus | Director | A | — | — |
| 2026-03-02 | Stacey D. Stewart | Director | A | — | — |
| 2026-03-02 | Wayde D. McMillan | Director | A | — | — |
| 2026-03-02 | Charles J Dockendorff | Director | A | — | — |
| 2026-03-02 | Anne M. Liddy | General Counsel | F | — | — |
| 2026-03-02 | Christiana Stamoulis | Director | A | — | — |
| 2026-02-12 | Mark W. Horvath | President, Breast & Skeletal | F | — | — |
| 2026-02-03 | Diana De Walt | SVP, Human Resources | F | — | — |
| 2026-02-03 | Diana De Walt | SVP, Human Resources | F | — | — |
| 2025-12-16 | Brandon Schnittker | President, GYN Surgical | F | — | — |
| 2025-11-18 | Karleen Marie Oberton | Chief Financial Officer | F | — | — |
| 2025-11-18 | Jennifer M Schneiders | President, Diag. Solutions | F | — | — |
| 2025-11-18 | BENJAMIN JORDAN COHN | Principal Accounting Officer | F | — | — |
| 2025-11-18 | Anne M. Liddy | General Counsel | F | — | — |
| 2025-11-18 | Jan Verstreken | Group President, International | F | — | — |
| 2025-11-18 | Essex D Mitchell | Chief Operating Officer | F | — | — |
| 2025-11-18 | Brandon Schnittker | President, GYN Surgical | F | — | — |
| 2025-11-18 | STEPHEN P MACMILLAN | Chairman, President and CEO | F | — | — |
| 2025-11-12 | Mark W. Horvath | President, Breast & Skeletal | A | — | — |
| 2025-11-12 | BENJAMIN JORDAN COHN | Principal Accounting Officer | MIXED | — | — |
| 2025-11-12 | Jan Verstreken | Group President, International | MIXED | — | — |
| 2025-11-12 | Essex D Mitchell | Chief Operating Officer | MIXED | — | — |
| 2025-11-12 | Jennifer M Schneiders | President, Diag. Solutions | MIXED | — | — |
| 2025-11-12 | Anne M. Liddy | General Counsel | MIXED | — | — |
| 2025-11-12 | Karleen Marie Oberton | Chief Financial Officer | MIXED | — | — |
| 2025-11-12 | STEPHEN P MACMILLAN | Chairman, President and CEO | MIXED | — | — |
| 2025-11-12 | Brandon Schnittker | President, GYN Surgical | MIXED | — | — |
| 2025-11-06 | BENJAMIN JORDAN COHN | Principal Accounting Officer | A | — | — |
| 2025-11-06 | Jan Verstreken | Group President, International | A | — | — |
| 2025-11-06 | Mark W. Horvath | President, Breast & Skeletal | A | — | — |
| 2025-11-06 | Karleen Marie Oberton | Chief Financial Officer | A | — | — |
| 2025-11-06 | Essex D Mitchell | Chief Operating Officer | A | — | — |
| 2025-11-06 | STEPHEN P MACMILLAN | Chairman, President and CEO | A | — | — |
| 2025-10-22 | Christiana Stamoulis | Director | MIXED | — | — |
| 2025-09-23 | STEPHEN P MACMILLAN | Chairman, President and CEO | MIXED | — | — |
| 2025-06-03 | Brandon Schnittker | Div. President, GYN Surgical | F | — | — |
| 2025-05-09 | Martin D Madaus | Director | Buy | — | — |
| 2025-04-09 | Wayde D. McMillan | Director | A | — | — |
| 2025-02-28 | Christiana Stamoulis | Director | A | — | — |
| 2025-02-28 | Stacey D. Stewart | Director | A | — | — |
| 2025-02-28 | Amy McBride Wendell | Director | A | — | — |
| 2025-02-28 | Martin D Madaus | Director | A | — | — |
| 2025-02-28 | LUDWIG HANTSON | Director | A | — | — |
| 2025-02-28 | Nanaz Mohtashami | Director | A | — | — |
| 2025-02-28 | Charles J Dockendorff | Director | A | — | — |
| 2025-02-12 | Mark W. Horvath | Div. Pres., Breast & Skeletal | A | — | — |
| 2024-12-17 | Brandon Schnittker | Div. President, GYN Surgical | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 34,154,879 | — |
| — | 10%+ Owner | 28,154,879 | — |
| — | Chairman, President and CEO | 2,570,666 | — |
| — | Executive VP and CFO | 875,306 | — |
| — | CEO and President | 421,438 | — |
| — | Chief Technical Officer | 201,648 | — |
| — | General Counsel | 182,514 | — |
| — | Chief Financial Officer | 150,735 | — |
| — | Executive Chairman | 136,935 | — |
| — | Group President, International | 134,039 | — |
| — | Director | 132,927 | — |
| — | Chief Financial Officer | 112,244 | — |
| — | COO | 107,560 | — |
| — | Chief Operating Officer | 77,610 | — |
| — | Group Pres, Global Diagnostics | 74,858 | — |
| — | Division Pres., Breast Health | 70,484 | — |
| — | Director | 65,052 | — |
| — | SVP and GM of Diagnostics | 61,674 | — |
| — | GSVP & GM Service & Operations | 59,271 | — |
| — | SVP, Chief Accounting Officer | 58,498 | — |
| — | Div President & GM, Diagnostic | 55,753 | — |
| — | Director | 55,595 | — |
| — | Group VP & GM, Women's Health | 53,645 | — |
| — | Director | 50,526 | — |
| — | Director | 49,259 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HOLX quote page; the site-wide leaderboard is on the insider transactions hub.